Blume-Jensen Peter 4

What Happened
Peter Blume-Jensen, President, CEO and a director of Acrivon Therapeutics (ACRV), had 13,729 restricted shares withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting. The shares were valued at $1.79 each, for a total withholding of approximately $24,575. This transaction is coded F (tax withholding) — a routine disposition to cover tax liability, not an open-market sale.

Key Details

• Transaction date: 2026-05-21; Filing date: 2026-05-26 (filed within the required reporting window).
• Shares withheld/disposed: 13,729 at $1.79 each; total ≈ $24,575.
• Transaction code: F — shares withheld to satisfy tax withholding on vested restricted stock units (see footnote F1).
• Shares owned after transaction: not specified in the provided details.
• Footnotes: F1 confirms shares were withheld to satisfy mandatory tax withholding on vesting. F2/F3 note certain securities are held by the insider's spouse (each spouse disclaims beneficial ownership of the other’s holdings except for pecuniary interest).

Context
Tax withholding on vested RSUs is a common administrative action and does not represent a voluntary sale into the market or a directional trading signal. For retail investors, this type of filing typically reflects routine compensation settlement rather than a change in the insider’s view of the company.